comprehensive -WSS

comprehensive

author：entertainment 2025-10-03 00:39:56 - browse：49

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： 'Essentially witchcraft:' A former naturopath takes on the field

focus

WSS

Coercive sterilizations revealed by STAT prompt outrage

Medical device trials still don't enroll enough women, study finds

Medical device trials still don't enroll enough women, study finds

STAT Virtual Event: ASCO Recap, Live!

Food makers tried to stack nutrition panel with preferred experts

New Covid vaccine is recommended for everyone 6 months or older

Wikipedia

comprehensive

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Stephen Quake on the Chan Zuckerberg quest to conquer disease

BioMarin wins approval for gene therapy to treat hemophilia A

My daughter's legacy lives on through her writing, phage therapy

United colonoscopy coverage change 'may cost lives,' doctors say

How to make the FDA’s new prescription one

Dobbs anniversary: the lost opportunity of abortion as health care

Statins may not be needed by millions of people, study suggests

Alkermes shareholders re

Pharma companies must ensure equitable access to obesity drugs

leisure time

Walmart eyes Medicare Advantage provider ChenMed

FDA approves updated Covid vaccines

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Teladoc has a new CEO, but challenges remain the same

White House touts steps to stem shortages of cancer treatments

Health care court cases: Humana, Sutter, Novant

focus

entertainment

leisure time

focus